IL110392A - Nucleicides 9 - -N bicycles used as selective inhibitors of pro-inflammatory cytokines - Google Patents

Nucleicides 9 - -N bicycles used as selective inhibitors of pro-inflammatory cytokines

Info

Publication number: IL110392A
Authority: IL; Israel
Prior art keywords: compound; amino; purin; exo; compound according
Prior art date: 1993-07-23

Application number

IL11039294A

Other languages

English (en)

Hebrew (he)

Other versions

IL110392A0 (en

Original Assignee

Merrell Dow Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-23

Filing date

1994-07-21

Publication date

2001-01-28

1994-07-21 Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma

1994-10-21 Publication of IL110392A0 publication Critical patent/IL110392A0/xx

2001-01-28 Publication of IL110392A publication Critical patent/IL110392A/en

Links

102000004127 Cytokines Human genes 0.000 title abstract description 23
108090000695 Cytokines Proteins 0.000 title abstract description 23
230000000770 proinflammatory effect Effects 0.000 title abstract description 7
229940124639 Selective inhibitor Drugs 0.000 title abstract description 4
150000001875 compounds Chemical class 0.000 claims description 168
-1 C02H Chemical compound 0.000 claims description 59
239000001257 hydrogen Substances 0.000 claims description 59
229910052739 hydrogen Inorganic materials 0.000 claims description 59
238000002360 preparation method Methods 0.000 claims description 42
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 35
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
238000011282 treatment Methods 0.000 claims description 25
229910003204 NH2 Inorganic materials 0.000 claims description 22
150000002431 hydrogen Chemical class 0.000 claims description 21
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 20
230000000694 effects Effects 0.000 claims description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
206010040070 Septic Shock Diseases 0.000 claims description 16
229910052757 nitrogen Inorganic materials 0.000 claims description 16
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 13
230000036303 septic shock Effects 0.000 claims description 13
XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 12
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 11
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
208000030507 AIDS Diseases 0.000 claims description 9
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 9
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 9
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 9
230000005764 inhibitory process Effects 0.000 claims description 9
206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 7
206010027202 Meningitis bacterial Diseases 0.000 claims description 6
201000009904 bacterial meningitis Diseases 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
206010054094 Tumour necrosis Diseases 0.000 claims description 4
AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 claims description 3
BAACXBNLIYYUFY-IQEPJDLESA-N (3r,6s)-3-(6-aminopurin-9-yl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-ol Chemical compound NC1=NC=NC2=C1N=CN2[C@H]1C2OC[C@H](O)C2OC1 BAACXBNLIYYUFY-IQEPJDLESA-N 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 claims 1
BAACXBNLIYYUFY-LNWAWGKBSA-N NC1=C2N=CN(C2=NC=N1)[C@H]1COC2C1OC[C@H]2O Chemical compound NC1=C2N=CN(C2=NC=N1)[C@H]1COC2C1OC[C@H]2O BAACXBNLIYYUFY-LNWAWGKBSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 8
239000002777 nucleoside Substances 0.000 abstract description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
238000006243 chemical reaction Methods 0.000 description 52
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
238000000034 method Methods 0.000 description 42
102100040247 Tumor necrosis factor Human genes 0.000 description 31
229940073584 methylene chloride Drugs 0.000 description 31
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 27
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
235000008504 concentrate Nutrition 0.000 description 26
239000012141 concentrate Substances 0.000 description 26
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
201000010099 disease Diseases 0.000 description 25
239000000741 silica gel Substances 0.000 description 25
229910002027 silica gel Inorganic materials 0.000 description 25
239000000203 mixture Substances 0.000 description 23
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 20
238000010992 reflux Methods 0.000 description 20
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 17
238000003818 flash chromatography Methods 0.000 description 17
125000006239 protecting group Chemical group 0.000 description 17
239000000243 solution Substances 0.000 description 16
239000000047 product Substances 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
239000000706 filtrate Substances 0.000 description 14
238000003756 stirring Methods 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
239000003638 chemical reducing agent Substances 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
239000003960 organic solvent Substances 0.000 description 11
239000003480 eluent Substances 0.000 description 10
239000002904 solvent Substances 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000001816 cooling Methods 0.000 description 9
239000012280 lithium aluminium hydride Substances 0.000 description 9
210000001616 monocyte Anatomy 0.000 description 9
230000003110 anti-inflammatory effect Effects 0.000 description 8
210000002540 macrophage Anatomy 0.000 description 8
125000001424 substituent group Chemical group 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
239000012267 brine Substances 0.000 description 7
150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
229930024421 Adenine Natural products 0.000 description 6
206010037660 Pyrexia Diseases 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000004913 activation Effects 0.000 description 6
229960000643 adenine Drugs 0.000 description 6
150000001450 anions Chemical class 0.000 description 6
150000001540 azides Chemical class 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000007858 starting material Substances 0.000 description 6
208000023275 Autoimmune disease Diseases 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000028993 immune response Effects 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
206010006895 Cachexia Diseases 0.000 description 4
206010009900 Colitis ulcerative Diseases 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
201000006704 Ulcerative Colitis Diseases 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000006020 chronic inflammation Effects 0.000 description 4
125000004093 cyano group Chemical group *C#N 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
239000000463 material Substances 0.000 description 4
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
238000010534 nucleophilic substitution reaction Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000000725 suspension Substances 0.000 description 4
201000008827 tuberculosis Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000030760 Anaemia of chronic disease Diseases 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 3
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
208000009329 Graft vs Host Disease Diseases 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
206010054272 Helicobacter gastritis Diseases 0.000 description 3
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
102000004889 Interleukin-6 Human genes 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
208000011200 Kawasaki disease Diseases 0.000 description 3
206010024229 Leprosy Diseases 0.000 description 3
239000012359 Methanesulfonyl chloride Substances 0.000 description 3
206010033767 Paracoccidioides infections Diseases 0.000 description 3
201000000301 Paracoccidioidomycosis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 3
206010044248 Toxic shock syndrome Diseases 0.000 description 3
231100000650 Toxic shock syndrome Toxicity 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
208000024248 Vascular System injury Diseases 0.000 description 3
208000012339 Vascular injury Diseases 0.000 description 3
208000010399 Wasting Syndrome Diseases 0.000 description 3
230000008578 acute process Effects 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
208000022400 anemia due to chronic disease Diseases 0.000 description 3
229940121363 anti-inflammatory agent Drugs 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
208000024908 graft versus host disease Diseases 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
229940100601 interleukin-6 Drugs 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
201000004015 melioidosis Diseases 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
239000012038 nucleophile Substances 0.000 description 3
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
230000005855 radiation Effects 0.000 description 3
201000004409 schistosomiasis Diseases 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 2
SPXOTSHWBDUUMT-UHFFFAOYSA-N 138-42-1 Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 2
RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 2
HWTDMFJYBAURQR-UHFFFAOYSA-N 80-82-0 Chemical compound OS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O HWTDMFJYBAURQR-UHFFFAOYSA-N 0.000 description 2
ONMOULMPIIOVTQ-UHFFFAOYSA-N 98-47-5 Chemical compound OS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 ONMOULMPIIOVTQ-UHFFFAOYSA-N 0.000 description 2
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102100025390 Integrin beta-2 Human genes 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
239000000284 extract Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000003871 sulfonates Chemical class 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
210000002437 synoviocyte Anatomy 0.000 description 2
201000004595 synovitis Diseases 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
BAACXBNLIYYUFY-TXEDRNKBSA-N (3r,6r)-3-(6-aminopurin-9-yl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-ol Chemical compound NC1=NC=NC2=C1N=CN2[C@H]1C2OC[C@@H](O)C2OC1 BAACXBNLIYYUFY-TXEDRNKBSA-N 0.000 description 1
LZQCROYPLWDYLE-IQEPJDLESA-N (3r,6s)-3-(6-aminopurin-9-yl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-thiol Chemical compound NC1=NC=NC2=C1N=CN2[C@H]1C2OC[C@H](S)C2OC1 LZQCROYPLWDYLE-IQEPJDLESA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
GFUHLPCICITTQQ-LNWAWGKBSA-N (3s,6r)-6-(6-aminopurin-9-yl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-carboxamide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1COC2C1OC[C@@H]2C(=O)N GFUHLPCICITTQQ-LNWAWGKBSA-N 0.000 description 1
JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
ZRXHLJNBNWVNIM-UHFFFAOYSA-N 3-methyl-1-benzofuran Chemical compound C1=CC=C2C(C)=COC2=C1 ZRXHLJNBNWVNIM-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
TWWQLRDQJBNUTQ-IIPFWGKHSA-N 9-[(3r,6s)-6-(dimethylamino)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]purin-6-amine Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1COC2C1OC[C@@H]2N(C)C TWWQLRDQJBNUTQ-IIPFWGKHSA-N 0.000 description 1
UORSAMBQHXMDBI-RHRMWPKMSA-N 9-[(3r,6s)-6-methylsulfanyl-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]purin-6-amine Chemical compound C1=NC2=C(N)N=CN=C2N1[C@H]1C2OC[C@H](SC)C2OC1 UORSAMBQHXMDBI-RHRMWPKMSA-N 0.000 description 1
KYIMWQJVRBCKNY-RYEKAPQHSA-N 9-[(3s,6r)-3-(methylamino)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]purin-6-amine Chemical compound C1=NC2=C(N)N=CN=C2N1[C@H]1C2OC[C@H](NC)C2OC1 KYIMWQJVRBCKNY-RYEKAPQHSA-N 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
PTCSLWKLBTWXOP-ZZCHAQKRSA-N Cl.Cl.NC1=NC=NC2=C1N=CN2[C@H]1C2OC[C@H](O)C2OC1 Chemical compound Cl.Cl.NC1=NC=NC2=C1N=CN2[C@H]1C2OC[C@H](O)C2OC1 PTCSLWKLBTWXOP-ZZCHAQKRSA-N 0.000 description 1
GRKANJDTVIJAAJ-UHFFFAOYSA-N Cl.Cl.OC12CCCC1CCC2 Chemical compound Cl.Cl.OC12CCCC1CCC2 GRKANJDTVIJAAJ-UHFFFAOYSA-N 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010016207 Familial Mediterranean fever Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010029538 Non-cardiogenic pulmonary oedema Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000700605 Viruses Species 0.000 description 1
DROSKPQSEXPWEI-RYEKAPQHSA-N [(3S,6R)-6-(6-aminopurin-9-yl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]methanol Chemical compound NC1=NC=NC2=C1N=CN2[C@H]1C2OC[C@H](CO)C2OC1 DROSKPQSEXPWEI-RYEKAPQHSA-N 0.000 description 1
AVNMMOZGJYDWAN-LNWAWGKBSA-N [(3s,6r)-6-(6-aminopurin-9-yl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]-diazonioazanide Chemical compound NC1=NC=NC2=C1N=CN2[C@H]1C2OC[C@H](N=[N+]=[N-])C2OC1 AVNMMOZGJYDWAN-LNWAWGKBSA-N 0.000 description 1
JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000006041 cell recruitment Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
238000010568 chiral column chromatography Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
238000012926 crystallographic analysis Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
102000036444 extracellular matrix enzymes Human genes 0.000 description 1
108091007167 extracellular matrix enzymes Proteins 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
QYRFJLLXPINATB-UHFFFAOYSA-N hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride Chemical compound Cl.Cl.NC1=C(F)C(N)=C(F)C(F)=C1F QYRFJLLXPINATB-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000002134 immunopathologic effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
210000004980 monocyte derived macrophage Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
QGZWYBQTXJMHIW-UHFFFAOYSA-N octane-3-thiol Chemical compound CCCCCC(S)CC QGZWYBQTXJMHIW-UHFFFAOYSA-N 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
150000002924 oxiranes Chemical group 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
229910052760 oxygen Chemical group 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229960001476 pentoxifylline Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)

IL11039294A 1993-07-23 1994-07-21 Nucleicides 9 - -N bicycles used as selective inhibitors of pro-inflammatory cytokines IL110392A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9734093A	1993-07-23	1993-07-23

Publications (2)

Publication Number	Publication Date
IL110392A0 IL110392A0 (en)	1994-10-21
IL110392A true IL110392A (en)	2001-01-28

Family

ID=22262875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11039294A IL110392A (en)	1993-07-23	1994-07-21	Nucleicides 9 - -N bicycles used as selective inhibitors of pro-inflammatory cytokines

Country Status (15)

Country	Link
US (1)	US6420373B1 (de)
EP (1)	EP0710239B1 (de)
JP (2)	JP3696882B2 (de)
KR (1)	KR100340374B1 (de)
AT (1)	ATE176668T1 (de)
AU (1)	AU683287B2 (de)
CA (1)	CA2166692C (de)
DE (1)	DE69416518T2 (de)
DK (1)	DK0710239T3 (de)
ES (1)	ES2132419T3 (de)
GR (1)	GR3029454T3 (de)
IL (1)	IL110392A (de)
TW (1)	TW397833B (de)
WO (1)	WO1995003304A1 (de)
ZA (1)	ZA945246B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2022497A (en) *	1996-03-13	1997-10-01	Novo Nordisk A/S	A method of treating disorders related to cytokines in mammals
WO1997033591A1 (en) *	1996-03-13	1997-09-18	Novo Nordisk A/S	A method of treating disorders related to cytokines in mammals
GB9813554D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
WO2000068230A1 (en) *	1999-05-05	2000-11-16	Darwin Discovery Limited	9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
US7087589B2 (en)	2000-01-14	2006-08-08	The United States Of America As Represented By The Department Of Health And Human Services	Methanocarba cycloakyl nucleoside analogues
US20070042978A1 (en) *	2002-12-19	2007-02-22	Jean-Philippe Girard	Nf-hev compositions and methods of use
EP2664340B1 (de)	2005-06-24	2020-02-12	Duke University	System zur direkten Heilmittelverabreichung auf der basis wärmegesteuerter Biopolymere
TWI429404B (zh) *	2008-03-03	2014-03-11	Senomyx Inc	異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
US8518957B2 (en)	2009-12-02	2013-08-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
US8822460B2 (en) *	2012-04-06	2014-09-02	Janssen Pharmaceutica Nv	Fused cyclopentyl antagonists of CCR2
EP2888005B1 (de) *	2012-08-22	2019-04-03	Merck Sharp & Dohme Corp.	Neuartige azabenzimidazol-hexahydrofuro[3,2-b]furan-derivate
RU2015139514A (ru) *	2013-03-05	2017-04-07	Арчер Дэниелс Мидлэнд Компани	Монотрифлаты изогексида и способ их синтеза
WO2015132799A2 (en)	2014-02-03	2015-09-11	Cadila Healthcare Limited	Novel heterocyclic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3028273A1 (de)	1980-07-25	1982-02-25	Fa. Dr. Willmar Schwabe, 7500 Karlsruhe	Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
DE3028288A1 (de)	1980-07-25	1982-02-25	Fa. Dr. Willmar Schwabe, 7500 Karlsruhe	Gegebenenfalls n-substituierte aminodesoxy-1.4;3.6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und deren verwendung
WO1989007102A1 (en) *	1988-02-08	1989-08-10	Schering Corporation	Nulceosidetype compounds which are phosphodiesterase inhibitors
US5091431A (en)	1988-02-08	1992-02-25	Schering Corporation	Phosphodiesterase inhibitors

1994
- 1994-06-24 ES ES94923241T patent/ES2132419T3/es not_active Expired - Lifetime
- 1994-06-24 DE DE69416518T patent/DE69416518T2/de not_active Expired - Lifetime
- 1994-06-24 WO PCT/US1994/007147 patent/WO1995003304A1/en not_active Ceased
- 1994-06-24 AT AT94923241T patent/ATE176668T1/de not_active IP Right Cessation
- 1994-06-24 AU AU73167/94A patent/AU683287B2/en not_active Ceased
- 1994-06-24 KR KR1019960700346A patent/KR100340374B1/ko not_active Expired - Fee Related
- 1994-06-24 DK DK94923241T patent/DK0710239T3/da active
- 1994-06-24 JP JP50515695A patent/JP3696882B2/ja not_active Expired - Fee Related
- 1994-06-24 CA CA002166692A patent/CA2166692C/en not_active Expired - Fee Related
- 1994-06-24 EP EP94923241A patent/EP0710239B1/de not_active Expired - Lifetime
- 1994-07-18 ZA ZA945246A patent/ZA945246B/xx unknown
- 1994-07-19 TW TW083106593A patent/TW397833B/zh not_active IP Right Cessation
- 1994-07-21 IL IL11039294A patent/IL110392A/en not_active IP Right Cessation
1995
- 1995-01-13 US US08/372,712 patent/US6420373B1/en not_active Expired - Fee Related
1999
- 1999-02-19 GR GR990400539T patent/GR3029454T3/el unknown
2004
- 2004-06-09 JP JP2004171934A patent/JP2004315538A/ja active Pending

Also Published As

Publication number	Publication date
DE69416518T2 (de)	1999-07-01
AU7316794A (en)	1995-02-20
EP0710239B1 (de)	1999-02-10
ZA945246B (en)	1995-03-20
WO1995003304A1 (en)	1995-02-02
IL110392A0 (en)	1994-10-21
GR3029454T3 (en)	1999-05-28
JP3696882B2 (ja)	2005-09-21
AU683287B2 (en)	1997-11-06
JPH09500643A (ja)	1997-01-21
CA2166692C (en)	1999-01-26
US6420373B1 (en)	2002-07-16
ES2132419T3 (es)	1999-08-16
DK0710239T3 (da)	1999-09-20
EP0710239A1 (de)	1996-05-08
JP2004315538A (ja)	2004-11-11
CA2166692A1 (en)	1995-02-02
DE69416518D1 (de)	1999-03-25
TW397833B (en)	2000-07-11
ATE176668T1 (de)	1999-02-15
KR100340374B1 (ko)	2002-11-13

Legal Events

Date	Code	Title
2001-06-14	FF	Patent granted
2001-07-24	KB	Patent renewed
2004-09-27	KB	Patent renewed
2009-08-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
SU1364238A3 (ru)	1987-12-30	Способ получени производных пиримидо @ 4,5- @ хинолина или их оптически активных изомеров,или их фармацевтически приемлемых аддитивных солей кислоты
EP0710239B1 (de)	1999-02-10	Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
JP2000501694A (ja)	2000-02-15	複素環置換シクロペンタン化合物
KR100249111B1 (ko)	2000-08-01	면역억제제로서 유용한 카르보시클릭 아데노신 동족체
EP2391212A1 (de)	2011-12-07	Verbrückte verbindungen als hiv-integrase-hemmer
US5629304A (en)	1997-05-13	Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US6541482B2 (en)	2003-04-01	Carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
JPH0269496A (ja)	1990-03-08	イミダゾ〔４，５―ｂ〕ピリジン誘導体
JP3273108B2 (ja)	2002-04-08	新規ピリド〔２，３−ｄ〕ピリミジン誘導体及びその製造方法
AU677732B2 (en)	1997-05-01	6-oxo-nucleosides useful as immunosuppressants
NZ269335A (en)	1997-12-19	Purine and analogues substituted in position-9 by dioxabicyclic and carbobicyclic moieties
RU2768451C1 (ru)	2022-03-24	Селективный антагонист рецепторов типа A2A
CN110903289B (zh)	2023-02-03	嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途
CN121219307A (zh)	2025-12-26	亲环蛋白抑制剂及其用途
CN116120327A (zh)	2023-05-16	β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用
JPH08269083A (ja)	1996-10-15	Ｎ６−置換アデノシン誘導体
CZ2000231A3 (cs)	2000-07-12	Nové sloučeniny